Clinical Trial Update: ConTTRibute: A Global Observational Study of Patients With Transthyretin (TTR)-Mediated Amyloidosis (ATTR Amyloidosis)

View source ↗

Summary

A global observational study (ConTTRibute) of patients with transthyretin-mediated amyloidosis (ATTR amyloidosis) that is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin-mediated Amyloidosis

Snippet

Sponsor: Alnylam Pharmaceuticals | Conditions: Transthyretin-Mediated Amyloidosis, ATTR Amyloidosis | Status: RECRUITING